Title: Resverlogix Corp.
1Resverlogix Corp.
TSX RVX
2About Company
- Resverlogix based in Calgary-based TSX-list
biotech company that is a world-leader in the
development of an oral therapy to actually
regress plaque build-ups in a persons arteries. - Plaque build-up also known as atherosclerosis, is
the leading cause of cardiovascular disease
(CVD), the leading killer of men and women in the
industrialized world with over 18 million deaths
reported in 2005 (World Health Organization).
3About Company
NexVas Plaque Regression (NexVas PR), is a novel
technology platform with drugs that increase
apolipoproteinA-I (ApoA-I) to reduce
atherosclerosis (fatty plaque build-up in the
arteries), which is the leading cause of CVD.
ApoA-I is the key protective protein of high
density lipoprotein (HDL), commonly known as the
good cholesterol. Current drugs on the market
only manage atherosclerosis burden but they have
very limited or no effect on atherosclerosis
regression. NexVas PR aims to manage and regress
atherosclerosis. Resverlogixs lead ApoA-I drug
RVX-208 recently completed a Phase 1b/2a human
clinical trial.
4Management
Donald J. McCaffrey President and CEO,
Co-Founder Don is Resverlogixs strategic leader,
founder, mentor and the overall heart of the
company. Norman C.W. Wong, M.D., FRCP Chief
Scientific Officer Co-Founder Norman is the
visionary for the scientific development of
Resverlogixs therapeutic platforms. Jan O.
Johansson, M.D., Ph.D. Senior Vice President
Medical Affairs Jan oversees the clinical and
regulatory development, and provides scientific
guidance to the corporation.
5Management
Kenneth Lebioda, BA Senior VP Business
Corporate Development Ken is responsible for the
business and market development of the companys
technology pipeline and alliance
management. Gregory S. Wagner, Ph.D.,
DABT Senior VP Research Development Greg
oversees the companys preclinical programs and
provides extensive expertise in the areas of drug
development, regulatory filings, and
toxicology. Dr. F. Allan Gordon, M.D.,
Ph.D Senior Vice President of Clinical
Development Allan will lead Resverlogix through
clinical development.
6Share Structure Financials
- Shares Outstanding 39.4M
- Shares Fully Diluted 49.6M
- Options/Warrants 10.2M
- Current Price 2.81
- 52 Week High/Low 6.10/1.50
- 3 mo daily volume 73,000
- Cash on Hand 7M
71-Year Stock Chart
8Calendar of Catalysts
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
X X X
- Sept Announced successful 1b/2a human clinical
trial - Nov Preparation of Stage 2 Human Clinical Trial
by IVUS (intravascular ultrasound) - Big Pharma could invest at any time
9Why Invest Now?
- Recent US analyst coverage by Rodman Renshaw
with 1-year 8 price target - Moving towards a Stage 2 Human Clinical Trial
(IVUS) - Big Pharma could invest at any time as financing
will need to be done prior to IVUS - 1-per-cent and 5-per-cent regression of
atherosclerosis would save the U.S. health care
system between 22.9-billion (U.S.) and
76.8-billion (U.S.) annually
10Contact
- Contact Graeme A. Dick
- Website www.resverlogix.com
- Phone 403-561-8989
- Email graeme_at_briscocapital.com
TSX RVX